AstraZeneca’s Supplemental Biologics License Application, or sBLA, for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray, has been accepted for review by the U.S. Food and Drug Administration, the company announced. “If approved, FluMist will be the first flu vaccine available to be self-administered by eligible patients or administered by caregivers, adding an additional option to be vaccinated against influenza,” the company said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca to hold a virtual meeting
- AstraZeneca: Enhertu demonstrated meaningful survival in Phase II trial
- AstraZeneca says Dato-DXd improved progression-free survival in NSCLC trial
- AstraZeneca reports ‘positive’ results from TROPION-Breast01 Phase III trial
- AstraZeneca, Daiichi Sankyo’s Enhertu approved in EU for certain NSCLC